GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular–kidney–metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide an...

Descripción completa

Detalles Bibliográficos
Autores: Abasheva, Daria, Ortiz Arduán, Alberto, Fernández Fernández, Beatriz
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:dnet:biblosearchi::f02dd69b5884029127206755d4f94a3f
Acceso en línea:https://hdl.handle.net/10486/759340
https://dx.doi.org/10.1093/ckj/sfae296
Access Level:acceso abierto
Palabra clave:chronic kidney disease
glucagon-like peptide-1 (GLP-1) receptor agonists
hypertension
obesity
overweight
Medicina
id ES_586cade318d3e62bb4469b2bb752991d
oai_identifier_str oai:dnet:biblosearchi::f02dd69b5884029127206755d4f94a3f
network_acronym_str ES
network_name_str España
repository_id_str
spelling GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesityAbasheva, DariaOrtiz Arduán, AlbertoFernández Fernández, Beatrizchronic kidney diseaseglucagon-like peptide-1 (GLP-1) receptor agonistshypertensionobesityoverweightMedicinaGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular–kidney–metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) ≥30 kg/m2] or with overweight (BMI ≥27 kg/m2) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others. Additionally, liraglutide and semaglutide are approved to reduce CVD risk in patients with CVD and T2DM. Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial). Thus, nephrologists should consider prescribing GLP-1 RAs to improve metabolic control, reduce CVD risk or improve kidney outcomes in three scenarios: patients with overweight and a related comorbid condition such as hypertension, dyslipidaemia or CVD, patients with obesity and patients with T2DM. This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM healthFunding was received from Sociedad Española de Nefrología (SEN), Sociedad Madrileña de Nefrología (SOMANE), Fundación Renal Iñigo Álvarez de Toledo (FRIAT), Comunidad de Madrid en Biomedicina P2022/BMD-7223, CIFRA_COR-CM; Instituto de Salud Carlos III (ISCIII) Fondo de investigación Sanitaria/Fondo Europeo de Desarrollo regional (FEDER) (PI20/00744, PI22/00469, PI22/00050, PI21/00251, PI23/00627), ERA-PerMed- JTC2022 (SPAREKID AC22/00027), SIGNAL (AC22/00028), RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union—NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR) and SPACKDc PMP21/00109, FEDER funds, COST Action PERMEDIK CA21165, supported by COST (European Cooperation in Science and Technology); PREVENTCKD Consortium Project ID: 101101220 Programme: EU4H DG/Agency: HADEA. KitNewCare, Project ID: 101137054, Call: HORIZON-HLTH-2023-CARE-04, Programme: HORIZON. DG/Agency: HADEA. PICKED Project ID 101168626 HORIZON-MSCA-2023-DN-01-01 MSCA Doctoral Networks 2023. This paper is part of a Supplement that was financially supported by the ERAOxford University PressEuropean Renal Association (ERA)Departamento de MedicinaFacultad de MedicinaComunidad de MadridGobierno de EspañaInstituto de Salud Carlos IIIEuropean Commission20242024-11-22research articlehttp://purl.org/coar/resource_type/c_2df8fbb1EVoRhttp://purl.org/coar/version/c_dc82b40f9837b551info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10486/759340https://dx.doi.org/10.1093/ckj/sfae29639583142reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Autónoma de MadridInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:dnet:biblosearchi::f02dd69b5884029127206755d4f94a3f2026-06-23T12:46:27Z
dc.title.none.fl_str_mv GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
title GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
spellingShingle GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, Daria
chronic kidney disease
glucagon-like peptide-1 (GLP-1) receptor agonists
hypertension
obesity
overweight
Medicina
title_short GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
title_full GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
title_fullStr GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
title_full_unstemmed GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
title_sort GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
dc.creator.none.fl_str_mv Abasheva, Daria
Ortiz Arduán, Alberto
Fernández Fernández, Beatriz
author Abasheva, Daria
author_facet Abasheva, Daria
Ortiz Arduán, Alberto
Fernández Fernández, Beatriz
author_role author
author2 Ortiz Arduán, Alberto
Fernández Fernández, Beatriz
author2_role author
author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
Comunidad de Madrid
Gobierno de España
Instituto de Salud Carlos III
European Commission
dc.subject.none.fl_str_mv chronic kidney disease
glucagon-like peptide-1 (GLP-1) receptor agonists
hypertension
obesity
overweight
Medicina
topic chronic kidney disease
glucagon-like peptide-1 (GLP-1) receptor agonists
hypertension
obesity
overweight
Medicina
description Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular–kidney–metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) ≥30 kg/m2] or with overweight (BMI ≥27 kg/m2) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others. Additionally, liraglutide and semaglutide are approved to reduce CVD risk in patients with CVD and T2DM. Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial). Thus, nephrologists should consider prescribing GLP-1 RAs to improve metabolic control, reduce CVD risk or improve kidney outcomes in three scenarios: patients with overweight and a related comorbid condition such as hypertension, dyslipidaemia or CVD, patients with obesity and patients with T2DM. This review addresses the promising landscape of GLP-1 RAs to treat persons with overweight or obesity, with or without T2DM, within the context of CKD, assessing their safety and impact on weight, metabolic control, blood pressure and kidney and cardiovascular outcomes, as part of a holistic patient-centred approach to preserve CKM health
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-11-22
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
EVoR
http://purl.org/coar/version/c_dc82b40f9837b551
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10486/759340
https://dx.doi.org/10.1093/ckj/sfae296
39583142
url https://hdl.handle.net/10486/759340
https://dx.doi.org/10.1093/ckj/sfae296
identifier_str_mv 39583142
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
European Renal Association (ERA)
publisher.none.fl_str_mv Oxford University Press
European Renal Association (ERA)
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Autónoma de Madrid
instname_str Universidad Autónoma de Madrid
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408541508370432
score 15,81155

Similares en LA Referencia